Skip to main content
Lotus Pharm logo

Lotus Pharm — Investor Relations & Filings

Ticker · 1795 ISIN · TW0001795003 LEI · 984500BEECDBC04KP716 TW Manufacturing
Open in API
Filings indexed 2,730 across all filing types
Latest filing 2026-03-18 Annual Report
Country TW Taiwan
Listing TW 1795

About Lotus Pharm

http://www.lotuspharm.com.tw

Lotus Pharmaceutical Co., Ltd. is a global specialty organization focused on the development, manufacturing, and commercialization of high-barrier generic and specialty medicines. The company specializes in complex generics, with a primary focus on oncology, immunology, and addiction treatment. Its portfolio includes technically demanding products such as Lenalidomide, Suboxone, Nintedanib, and Vinorelbine, as well as an advancing pipeline of biosimilars and 505(b)(2) oncology candidates. Utilizing an integrated R&D and manufacturing platform, the company executes a "2x2" growth strategy centered on dual market expansion and product diversification. Its commercial footprint spans over 90 markets globally, maintaining a strong presence in the Asia-Pacific region and the United States. The company prioritizes high technical entry barriers and cost-effective therapeutic solutions to improve global patient access to essential medications.

Recent filings

Filing Released Lang Actions
115年03月法人說明會簡報 — 179520260318E001.pdf
Annual Report Classification · 95% confidence The document is titled '2025 Financial Results' and dated 18 Mar 2026, indicating it covers the full fiscal year 2025. It contains detailed financial data including revenue, EBITDA, net profit, EPS, segment performance, pipeline updates, licensing agreements, and outlook for 2026. The presence of comprehensive financial tables, business highlights, and management commentary on financial performance and future outlook strongly indicates this is a full annual financial report. The length of the document (11,900 characters) and the depth of financial and operational information confirm it is not a brief announcement or presentation but a substantive report. Therefore, the document fits the definition of an Annual Report (10-K). FY 2025
2026-03-18 Chinese
115年03月法人說明會簡報 — 179520260318M001.pdf
Annual Report Classification · 95% confidence The document is a detailed presentation of Lotus Pharmaceutical's 2025 financial results, operational highlights, product pipeline updates, and outlook for 2026. It includes comprehensive financial data such as consolidated income statements, revenue growth, EBITDA, net profit, EPS, and segment performance. The document also discusses business development, R&D progress, licensing agreements, and strategic outlook. The presence of detailed financial tables and substantive financial analysis indicates this is a comprehensive financial report for a fiscal year. The document is not merely an announcement or a brief summary but contains in-depth financial and operational information typical of an Annual Report. There is no indication that this is a transcript, proxy statement, or regulatory filing. Therefore, the document fits the definition of an Annual Report (10-K). FY 2025
2026-03-18 Chinese
115年03月法人說明會簡報
Investor Presentation Classification · 95% confidence The document is a listing from a public information observation station showing scheduled dates and details for company investor presentations (法人說明會) including links to presentation materials and webcast URLs. It references specific dates and times for investor meetings and provides access to presentation PDFs and video links. The content is focused on investor presentations explaining quarterly financial and operational status, not the full financial report itself. The document length is short (1258 characters) and it primarily serves as an announcement or schedule of investor presentations rather than containing detailed financial data or full transcripts. Therefore, the document best fits the category of Investor Presentation (IP).
2026-03-18 Chinese
114年度應收帳款周轉率
Regulatory Filings Classification · 90% confidence The document is very short (283 characters) and contains financial ratio data related to accounts receivable turnover and average collection days for two years. There is no indication of a full financial report, management discussion, or detailed analysis. It appears to be a brief financial metric disclosure, likely part of a regulatory or compliance filing rather than a full report. Given the brevity and nature of the content, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2026-03-14 Chinese
114年度存貨週轉率
Regulatory Filings Classification · 90% confidence The document is very short (312 characters) and contains a brief explanation about inventory turnover rates and average sales days, mentioning a merger completion affecting inventory levels. It does not contain comprehensive financial statements or detailed analysis. It appears to be a brief explanatory note or update rather than a full report. Given the short length and nature of the content, it is not an Annual Report, Interim Report, or detailed Management Report. It is also not a regulatory certification or voting result. The content is more of a brief operational or financial metric update with explanation, which fits best under Regulatory Filings (RNS) as a miscellaneous announcement that does not fit other categories.
2026-03-14 Chinese
114年度毛利率
Fund Information / Factsheet Classification · 90% confidence The document is very short (394 characters) and contains a simple financial summary table with annual revenue, cost, gross profit, and gross margin percentages for two years. There is no detailed financial statement, management discussion, or comprehensive report content. It appears to be a brief financial data snippet, likely a summary or factsheet. Given the brevity and nature of the content, it fits best as a Fund Information / Factsheet (FS) rather than a full Annual Report or Interim Report. There is no indication of it being an announcement or regulatory filing, nor does it contain detailed management or audit information.
2026-03-14 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.